PVCT — PROVECTUS BIOPHARMACEUTICALS, INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 315545 ·
Last close
$0.06
Market Cap
$26.48M
52W High
$0.08
52W Low
$0.05
ADV30
206,633
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,247,903 | -1,290,454 | 577,580 | 223,883 | 7,308,410 |
| Dec 2025 | 0 | — | -1,120,489 | -1,239,315 | 697,502 | 251,291 | 7,000,220 |
| Sep 2025 | 0 | — | -1,275,607 | -1,311,281 | 419,904 | 72,479 | 6,586,914 |
| Jun 2025 | 0 | — | -1,800,776 | -1,852,081 | 722,384 | 385,929 | 6,597,139 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,590,112
Investing CF
—
Financing CF
$2,343,763
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-264,144,266
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-5,444,727
Pretax Income TTM
$-5,644,471
Interest Exp TTM
$199,744
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$57,480
EBITDA
$-4,992,369
Free Cash Flow
$-609,803
Enterprise Value
$28,819,618
Total Cash
$223,883
Total Debt
$2,766,939
Shares Out
420,279,879
Trailing EPS
$-0.01
Book Value
$-0.02
ROE
—
ROA
-501.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,294,765 | -5,505,124 | 697,502 | 7,000,220 | — | -3,325,991 |
| Dec 2024 | 0 | -4,531,603 | -4,762,137 | 1,006,259 | 6,975,484 | — | -3,284,091 |
| Dec 2023 | 0 | -2,925,477 | -3,101,768 | 1,448,843 | 9,042,194 | — | -2,571,978 |
| Dec 2022 | 0 | -3,428,379 | -3,554,683 | 2,037,246 | 8,265,756 | — | -3,041,472 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACTU | ACTUATE THERAPEUTICS, INC. | $26.56M | $1.11 | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $26.26M | $0.84 | — |
| ABVC | ABVC BIOPHARMA, INC. | $26.26M | $1.01 | — |
| IGC | IGC Pharma, Inc. | $26.09M | $0.25 | — |
| QUCY | Quantum Cyber N.V. | $25.95M | $1.14 | — |
News headlines (Yahoo Finance, 1h cache)
VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase
2026-07-22 12:00 · Yahoo
Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose
2026-07-07 12:00 · Yahoo
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
2026-06-30 12:00 · Yahoo
Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
2026-06-25 12:00 · Yahoo
Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders
2026-06-08 12:00 · Yahoo
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
2026-05-18 12:00 · Yahoo
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium
2026-05-04 12:00 · Yahoo
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
2026-04-20 22:09 · Yahoo
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
2026-04-02 12:00 · Yahoo
Provectus: Q4 Earnings Snapshot
2026-03-26 10:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.